Videos

Overview of Treatment Options for Relapsed/Refractory Multiple Myeloma

Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.

Thomas G. Martin, MD;Ajay K. Nooka, MD;Jeremy Larsen, MD

Determining Transplant Ineligibility in Newly Diagnosed Multiple Myeloma

Key opinion leaders share comprehensive insight to the treatment armamentarium for patients with relapsed/refractory multiple myeloma.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Features of High-Risk Multiple Myeloma and Clinical Trial Landscape

Focused discussion on factors that aid in determining transplant ineligibility when a patient presents with newly diagnosed multiple myeloma.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Treatment Options for Frontline and Relapsed Multiple Myeloma

The expert panel provides clinical insights on the key features of high-risk multiple myeloma and a look toward the clinical trial landscape.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Overview of Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

An overview of multiple myeloma treatment options in the frontline and relapsed settings.

Thomas G. Martin, MD;Ajay K. Nooka, MD;Jeremy Larsen, MD

What is the Role of Transplant in Treating Patients With NDMM?

Experts Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, provide a broad overview of cytokine release syndrome as it relates to the management of multiple myeloma.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Patient Monitoring and Workup in Relapsed MM

Key opinion leaders in multiple myeloma management reflect on the current role of stem cell transplant in patients with newly diagnosed disease.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Role of Transplant in Multiple Myeloma

Experts on multiple myeloma discuss approaches to laboratory workup and patient monitoring at the time of relapse.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Physician Assistant Details Importance of AE Management in Follicular Lymphoma

Clinical experts examine the role of transplant in multiple myeloma and discuss key clinical trials and the impact of adding daratumumab to triplet therapy.

The education of patients on identifying and reporting adverse effects is a critical part of effective toxicity management.

Jennifer L. Garson, PA-C

Clinical Implications from the MAIA and SWOG S0777 Studies

The education of patients on identifying and reporting adverse effects is a critical part of effective toxicity management.

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD

Clinical Insights from the Results of the MASTER Trial

A summary of updates from the MAIA and SWOG S0777 studies, with a focus on efficacy and tolerability data.

Luciano Costa, MD, PhD;Timothy Schmidt, MD

Goals of Therapy and Treatment Options for Patients with Transplant-Ineligible NDMM

Thoughtful discussion centered around recently presented updates to the MASTER trial.

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD

When to Perform Molecular Testing in Relapsed AML

Joselle Cook, M.B.B.S and Matthew James Pianko, MD discuss available treatment options and goals of therapy for patients with transplant-ineligible NDMM.

Naval Daver, MD;Harry P. Erba, MD, PhD;Dan Pollyea, MD, MS;Eunice S. Wang, MD

An Introduction to NDMM: Treatment Options and Patient Risk Stratification

Harry P. Erba, MD, PhD, discusses the need to retest for mutations including IDH1, IDH2, FLT3, NPMI, and KMT2A rearrangement for patients with relapsed or refractory acute myeloid leukemia.

Luciano Costa, MD, PhD;Timothy Schmidt, MD

Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma

Luciano Costa, MD, PhD and Timothy Schmidt, MD introduce treatment regimen options and risk stratification for patients with transplant-eligible NDMM.

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

The Role of Molecular Testing in Diagnosing Acute Myeloid Leukemia

Closing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.

Naval Daver, MD;Harry P. Erba, MD, PhD;Dan Pollyea, MD, MS;Eunice S. Wang, MD

CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma

A panel of clinical experts provide insights about the importance of molecular and cytogenetic testing in diagnosing acute myeloid leukemia and in determining the best treatment plan.

$CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma$

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma

Naresh Bumma, MD, reviews how he selects between CAR T-cell therapy and bispecific agents for patients with refractory multiple myeloma.

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

Examining the Role of the Physician Assistant in Follicular Lymphoma

Naresh Bumma, MD, details other bispecific agents on the horizon for relapsed multiple myeloma treatment.

One role of a physician assistant is to help patients understand their treatment and the results they’re presented with.

Jennifer L. Garson, PA-C

An Introduction to Treatment Strategies for Patients with NDMM

One role of a physician assistant is to help patients understand their treatment and the results they’re presented with.

Sagar Lonial, MD, FACP;Nisha Joseph, MD;Jonathan Kaufman, MD;Ajay K. Nooka, MD

Patient Case Introduction: A 65-year-old Female Diagnosed with Transplant-eligible NDMM

Nisha Joseph, MD leads an introduction to induction regimen options for patients with transplant-eligible NDMM.

Sagar Lonial, MD, FACP;Nisha Joseph, MD;Jonathan Kaufman, MD;Ajay K. Nooka, MD

Patient Case 3: A 52-Year-Old Treated with a Non-BCMA-Targeting Bispecific

Moderator Sagar Lonial, MD, FACP, and colleagues engage with the first patient case: a 65-year-old female diagnosed with transplant-eligible NDMM.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Managing Infections and Other Toxicities Associated with Bispecifics in MM

Maria-Victoria Mateos, MD, PhD, presents the case of a 52-year-old patient with penta-exposed MM who receives treatment with a non-BCMA-targeting bispecific.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

The Development of Bispecifics-Based Combination Therapies in MM

Jeremy Larsen, MD, discusses the management of infections, neurotoxicity, and other side effects associated with bispecifics in patients with R/R MM, including the need for prophylactic antimicrobials and monitoring of immunoglobulin levels.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Best Practices for Transition of Care in Patients with MM on Teclistamab

Dr Maria-Victoria Mateos shares her expert perspectives on current efficacy and safety data on combination strategies with bispecifics in relapsed/refractory MM.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD